Daré Bioscience · pitchdeck
Dare Bioscience | Investor Presentation Deck | 54 slides
54 pages · 4 arc beats · 1 loops
Dare Bioscience | Investor Presentation Deck | 54 slides
Daré Bioscience · 2023-02 arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
124681012141618202224262830323436384042444648505254
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 4 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits — 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides — 0/1 slides
Team 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides — 0/1 slides
Slide inventory
54 every slide · same image gating as the playbook
02
Text-heavy legal/disclaimer slide with multi-paragraph fine print and a subtle barcode-like background pattern. No data, charts, or imagery beyond the headline front_matter
04
The slide uses a contrast between the low research/pipeline investment (left) and the high market impact/purchasing power (right) to argue for efficiency.size_opportunity
05
The slide uses a comparative framework to show market potential by citing historical peak revenues of successful drugs.size_opportunity
Open slide detailBeat · Market Size
06
The slide uses a grid-like layout to organize product candidates by category.present_solution
07
The slide uses a numbered list for the thesis points and a separate callout box for milestones.summarize
08
The slide uses a Gantt-chart style visualization to show the progress of multiple drug candidates across clinical phases.plan_implementation
09
Includes specific financial terms of the collaboration and regulatory milestones.show_traction
10
The slide uses a structured layout to compare three distinct product pipelines.plan_implementation
11
The slide uses a two-tier layout to distinguish between Phase 1 and Preclinical development stages.plan_implementation
12
The slide uses a process-like flow to connect internal strengths to external market validation.argue_timing
13
The slide uses a standard team/board layout with a logo cloud at the bottom to establish credibility.other
Open slide detailBeat · Team
15
The slide uses a simple list format to communicate upcoming program milestones.plan_implementation
17
The slide uses a structured comparison format to frame the medical problem and the proposed solution.frame_problem
18
Mentions Organon as the commercial partner leveraging the NEXPLANON sales team.present_solution
19
The slide highlights a key partnership milestone and the associated financial structure (upfront payment and potential milestones).show_traction
Open slide detailLoop · Cost Of Inaction
20
Standard pharmaceutical ISI (Important Safety Information) slide.other
Open slide detailLoop · Cost Of Inaction
21
This is a regulatory disclosure slide regarding drug safety in specific patient demographics.other
Open slide detailLoop · Cost Of Inaction
22
The slide uses a high-contrast design with a large yellow circle on the left and a deep blue background, emphasizing the product name and its core value proposipresent_solution
Open slide detailLoop · Cost Of Inaction
23
Includes a line chart of population projections and three circular callouts detailing specific product sales.size_opportunity
Open slide detailLoop · Cost Of Inaction
24
The slide uses a tree-like diagram to segment the total addressable market into specific contraceptive user groups.size_opportunity
Open slide detailLoop · Cost Of Inaction
25
The slide uses a vertical axis to represent effectiveness, positioning the company's product as a bridge between traditional barrier methods and the Copper IUD.compare_peers
Open slide detailLoop · Cost Of Inaction
26
The slide uses a comparison table structure to map desired product features to specific Ovaprene design attributes.present_solution
Open slide detailLoop · Cost Of Inaction
27
Includes details on milestone payments, royalties, and strategic support from Bayer.show_traction
Open slide detailLoop · Cost Of Inaction
28
Includes a testimonial quote from a Bayer executive.show_traction
Open slide detailLoop · Cost Of Inaction
29
Includes a data table comparing baseline PCT results with Ovaprene PCT results.plan_implementation
Open slide detailLoop · Cost Of Inaction
30
The slide highlights the lack of existing FDA-approved therapies for FSAD.present_solution
Open slide detailLoop · Cost Of Inaction
31
Uses a visual inequality symbol to emphasize the distinction between FSAD and HSDD.frame_problem
Open slide detailLoop · Cost Of Inaction
32
The slide uses a double-bordered box design to separate academic meta-analysis from commercial market research estimates.size_opportunity
Open slide detailLoop · Cost Of Inaction
33
The slide uses a light blue callout box to group the product benefits and highlights the lack of current FDA-approved treatments for FSAD.present_solution
Open slide detailLoop · Cost Of Inaction
34
The slide outlines the methodology and goals of a clinical trial, specifically mentioning the RESPOND study.show_traction
Open slide detailLoop · Cost Of Inaction
35
The slide uses clinical trial data to justify the pivot to a topical delivery mechanism.show_traction
Open slide detailLoop · Cost Of Inaction
36
Includes a table of pharmacokinetic parameters and a line chart showing plasma concentration over time.analyze_data
Open slide detailLoop · Cost Of Inaction
39
The slide uses a side-by-side comparison layout to contrast the biological route with the technical solution.present_solution
Open slide detailLoop · Cost Of Inaction
40
The slide frames the market opportunity and clinical need for a non-oral hormone therapy.frame_problem
Open slide detailLoop · Cost Of Inaction
41
The slide highlights statistically significant improvements (p<0.01) across multiple clinical endpoints.show_traction
Open slide detailLoop · Cost Of Inaction
42
The slide details the specific regulatory strategy for a pharmaceutical product, focusing on the 505(b)(2) pathway.plan_implementation
Open slide detailLoop · Cost Of Inaction
44
The slide uses a grid-based layout to organize product candidates by development stage (Phase 1 vs Preclinical).plan_implementation
Open slide detailLoop · Cost Of Inaction
45
The slide highlights the clinical need for non-daily dosing progesterone delivery systems.present_solution
Open slide detailLoop · Cost Of Inaction
46
The slide highlights a specific clinical need for breast cancer survivors.present_solution
Open slide detailLoop · Cost Of Inaction
47
Includes clinical trial data and comparative pharmacokinetic data against oral tamoxifen.analyze_data
Open slide detailLoop · Cost Of Inaction
48
Text-dense clinical study summary slide with a red banner headline and subtitle; reports specific quantitative outcomes (e.g. p=0.04, 36 days, 17 women, dose leanalyze_data
Open slide detailLoop · Cost Of Inaction
49
Includes regulatory disclaimer and multiple source citations.frame_problem
Open slide detailLoop · Cost Of Inaction
50
The slide uses a comparative framework to highlight the competitive advantage of the proposed product over the incumbent Depo-Provera.frame_problem
Open slide detailLoop · Cost Of Inaction
51
The slide outlines development phases from 2021 through 2026, including specific grant amounts.plan_implementation
Open slide detailLoop · Cost Of Inaction
52
The slide uses a callout box to highlight the mechanism and benefits of GML.present_solution
Open slide detailLoop · Cost Of Inaction
53
The slide highlights the clinical need for vaginal health solutions and the specific technical challenge of maintaining microbe viability in low-resource settinpresent_solution
Open slide detailLoop · Cost Of Inaction
54
The slide uses a play on the company name 'Dare' to create a brand slogan.inspire_vision
Open slide detailLoop · Cost Of Inaction